Walk it out: acute treadmill walking reduces state anxiety and improves mood in people with multiple sclerosis who have analogue generalized anxiety disorder.

Anxiety Stress CopingFeb 10, 2026 (epub)
Clinical ResearchPsychiatryNeurology

Petra Šilić, Robert W Motl

✦ AI-curated · Sources linked

In 30 seconds

This randomized, counterbalanced crossover experiment assessed whether a single bout of moderate-intensity treadmill walking affected anxiety and mood in people with multiple sclerosis prescreened for analogue generalized anxiety disorder. Participants completed 20 minutes of walking and seated quiet rest, with state anxiety and mood measured before, immediately after, and 20 minutes after each condition. Anxiety showed a significant condition-by-time interaction (F(2,34) = 5.96, p = .006, η² = .26); scores fell after walking, with no change after rest. Overall mood also improved after walking but not rest.

Key findings

  • State anxiety showed a significant condition-by-time interaction: F(2,34) = 5.96, p = .006, η² = .26.
  • Anxiety scores decreased immediately after walking (d = 1.00) and 20 minutes later (d = .75), with no change after seated rest.
  • Overall Profile of Mood States scores improved after walking but not after seated rest.

Why it matters

Anxiety in multiple sclerosis is described as prevalent and poorly managed. These experimental findings suggest that a brief bout of moderate-intensity walking can produce short-term improvements in state anxiety and mood in people with MS and analogue GAD, supporting further study of exercise as a potential management approach.

What to keep in mind

The study examined acute responses to a single exercise bout, so it does not establish whether repeated exercise provides sustained benefit or treats diagnosed GAD.

Source

Published in Anxiety Stress Coping. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.